Table 3.
Drug name | Target | Condition | Phase | Sample size | NCT number | Current status |
---|---|---|---|---|---|---|
Hedgehog inhibitors | ||||||
Vismodegib (GDC-0449) | Smoothened | Recurrent or refractory medulloblastoma | II | 31 | NCT00939484 | Completed, has results |
Basal cell carcinoma | 28 | NCT01700049 | Completed, has results | |||
Sarcoma | 78 | NCT01700049 | Completed, has results | |||
Recurrent small-cell lung carcinoma | 168 | NCT01700049 | Completed, has results | |||
Metastatic pancreatic cancer | 98 | NCT01088815 | Completed, has results | |||
Ovarian cancer | 104 | NCT00739661 | Completed, has results | |||
Metastatic colorectal cancer | 199 | NCT00636610 | Completed, has results | |||
Sonidegib (LDE225) | Basal cell carcinoma | II | 10 | NCT01350115 | Completed, has results | |
Relapsed medulloblastoma | 20 | NCT01708174 | Completed, has results | |||
Acute myeloid leukemia | 70 | NCT01826214 | Completed, has results | |||
Pancreatic adenocarcinoma | 20 | NCT01431794 | Completed, has results | |||
Advanced or metastatic hepatocellular carcinoma | 9 | NCT02151864 | Completed | |||
Recurrent plasma cell myeloma | 28 | NCT02086552 | Active, not recruiting, has results | |||
Advanced pancreatic cancer | 39 | NCT01485744 | Active, not recruiting | |||
Advanced breast cancer | I | 12 | NCT02027376 | Completed, has results | ||
Glasdegib | Acute myeloid leukemia | II | 255 | NCT01546038 | Completed, has results | |
BMS-833923 (XL139) | Solid tumors | II | 12 | NCT01413906 | Completed | |
Small-cell lung carcinoma | 5 | NCT00927875 | Completed | |||
Metastatic gastric, gastroesophageal, esophageal adenocarcinomas | 39 | NCT00909402 | Completed | |||
Advanced or metastatic basal cell carcinoma | 53 | NCT00670189 | Completed | |||
Leukemia | 70 | NCT01357655 | Terminated, has results | |||
Taladegib (LY2940680) | Localized esophageal or gastroesophageal junction cancer | II | 9 | NCT02530437 | Active, not recruiting | |
Small-cell lung carcinoma | 26 | NCT01722292 | Terminated, has results | |||
LEQ-506 | Solid tumors | I | 57 | NCT01106508 | Completed | |
G-024856 | BCC | I | ||||
Patidegib (IPI-926) | Basal cell carcinomas | II | 36 | NCT02828111 | Completed, has results | |
Metastatic or locally advanced chondrosarcoma | 105 | NCT01310816 | Completed | |||
Metastatic pancreatic cancer | 122 | NCT01130142 | Completed | |||
Recurrent head and neck cancer | I | 9 | NCT01255800 | Completed | ||
Notch inhibitors | ||||||
MK-0752 | γ-Secretase | Advanced breast cancer | I | 103 | NCT00106145 | Completed |
Pancreatic cancer | I | 44 | NCT01098344 | Completed | ||
Metastatic breast cancer | I/II | 30 | NCT00645333 | Completed, has results | ||
RO4929097 | Recurrent melanoma | II | 14 | NCT01196416 | Completed, has results | |
Advanced or metastatic sarcoma | 78 | NCT01154452 | Completed, has results | |||
Recurrent renal cell carcinoma | 12 | NCT01141569 | Completed, has results | |||
Advanced solid tumors | 20 | NCT01131234 | Completed | |||
Recurrent and/or metastatic epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer | 45 | NCT01175343 | Completed, has results | |||
Metastatic pancreas cancer | 18 | NCT01232829 | Completed, has results | |||
Recurrent colon cancer | 37 | NCT01116687 | Completed, has results | |||
Recurrent or refractory non-small-cell lung cancer | 7 | NCT01070927 | Completed | |||
Nirogacestat (PF-03084014) | Metastatic cancer pancreas | II | 3 | NCT02109445 | Terminated, has results | |
Fibromatosis | II | 17 | NCT01981551 | Active, not recruiting | ||
Triple-negative breast neoplasms | II | 19 | NCT02299635 | Terminated, has results | ||
LY900009 | Advanced cancer | I | 35 | NCT01158404 | Completed, has results | |
Crenigacestat (LY3039478) | Pan-Notch | Advanced solid tumor | I | 12 | NCT02836600 | Active, not recruiting |
T cell acute lymphoblastic leukemia, T cell lymphoblastic lymphoma | I/II | 36 | NCT02518113 | Completed, has results | ||
AL101 | Adenoid cystic carcinoma | II | 36 | NCT03691207 | Recruiting | |
CB-103 | Advanced or metastatic solid tumors and hematological malignancies | I/II | 165 | NCT03422679 | Recruiting | |
BMS-906024 | Advanced or metastatic solid tumors | I | 94 | NCT01292655 | Completed | |
Lymphoblastic leukemia, acute T cell | I | 31 | NCT01363817 | Completed | ||
Demcizumab (OMP-21M18) | DLL4 | Pancreatic cancer | II | 207 | NCT02289898 | Completed, has results |
Non-squamous, non-small-cell neoplasm of lung | II | 82 | NCT02259582 | Completed, has results | ||
Brontictuzumab (OMP-52M51) | Adenoid cystic carcinoma | Not applicable | 1 | NCT02662608 | Completed, has results | |
Enoticumab (MEDI528) | Advanced solid malignancies | I | 83 | NCT00871559 | Completed | |
MEDI0639 | Solid tumors | I | 58 | NCT01577745 | Completed, has results | |
Wnt inhibitors | ||||||
Ipafricept (OMP-54F28) | Wnt receptor | Solid tumors | I | 26 | NCT01608867 | Completed |
Pancreatic cancer | I | 26 | NCT02050178 | Completed | ||
Ovarian cancer | I | 37 | NCT02092363 | Completed | ||
Hepatocellular cancer | I | 10 | NCT02069145 | Completed | ||
Vantictumab (OMP-18R5) | Metastatic breast cancer | I | 37 | NCT01973309 | Completed | |
Solid tumors | I | 35 | NCT01345201 | Completed | ||
Pancreatic cancer | I | 30 | NCT02005315 | Completed | ||
PRI-724 | β-Catenin/CBP | Colorectal adenocarcinoma | II | 0 | NCT02413853 | Withdrawn |
Acute myeloid leukemia | 49 | NCT01606579 | Completed | |||
Solid tumors | 23 | NCT01302405 | Terminated | |||
Advanced pancreatic cancer | 20 | NCT01764477 | Completed | |||
CWP232291 | Acute myeloid leukemia | I | 69 | NCT01398462 | Completed | |
Multiple myeloma | I | 25 | NCT02426723 | Completed | ||
LGK974 | Porcupine | Metastatic colorectal cancer | I | 20 | NCT02278133 | Completed |
Pancreatic cancer | I | 170 | NCT01351103 | Recruiting | ||
ETC-1922159 | Solid tumors | I | 65 | NCT02521844 | Active, not recruiting | |
Other signaling pathways inhibitors | ||||||
Galunisertib (LY2157299) | TGF-β | Prostate cancer | II | 60 | NCT02452008 | Recruiting |
LY3200882 | Colorectal cancer | II | 31 | NCT04031872 | Not yet recruiting | |
AVID200 | Malignant solid tumor | I | 36 | NCT03834662 | Recruiting | |
Trabedersen (AP 12009) | Pancreatic neoplasms | II | 62 | NCT00844064 | Completed | |
Breast cancer | 16 | NCT01959490 | Completed, has results | |||
Glioblastoma | 141 | NCT00431561 | Completed | |||
Fresolimumab (GC1008) | Non-small-cell lung carcinoma | II | 60 | NCT02581787 | Recruiting | |
Metastatic Breast Cancer | 23 | NCT01401062 | Completed, has results | |||
Carcinoma Renal cell Melanoma |
29 | NCT00356460 | Completed | |||
Vactosertib (TEW-7197) | Advanced-stage solid tumors | I | 35 | NCT02160106 | Completed | |
NIS793 |
Breast cancer Lung cancer Hepatocellular cancer |
I | 220 | NCT02947165 | Recruiting | |
Ruxolitinib | JAK | Metastatic breast cancer | III | 29 | NCT01594216 | Completed |
Myeloproliferative neoplasms | 309 | NCT00952289 | Completed, has results | |||
AZD4205 | Advanced non-small-cell lung cancer | II | 120 | NCT03450330 | Recruiting | |
SAR302503 | Hematopoietic neoplasm | II | 97 | NCT01523171 | Completed | |
SB1518 | JAK/FLT3 | Acute myelogenous leukemia | II | 76 | NCT00719836 | Completed |
PI3K inhibitors | ||||||
Alpelisib | PI3K | Advanced breast cancer | II | 90 | NCT03386162 | Recruiting |
Buparlisib (BKM120) | Triple-negative metastatic breast cancer | II | 50 | NCT01629615 | Completed | |
BYL719 | Advanced or metastatic gastric cancer | I | 18 | NCT01613950 | Completed | |
SF1126 | Advanced or metastatic solid tumors | I | 44 | NCT00907205 | Completed | |
SAR245409 | PI3K and mTOR | Advanced or metastatic solid tumors | I | 146 | NCT01390818 | Completed, has results |
EGFR inhibitors | ||||||
Bevacizumab | EGFR | Breast cancer | I | 75 | NCT01190345 | Completed |
Matuzumab (EMD 72000) | Esophageal cancer | II | 72 | NCT00215644 | Completed, has results | |
Non-small-cell lung carcinoma | 150 | NCT00111839 | Completed, has results | |||
Metabolism inhibitors | ||||||
Venetoclax (ABT-199) | BCL-2 | Acute myelogenous leukemia | II | 32 | NCT01994837 | Completed, has results |
Pegzilarginase | Recombinant pegylated arginase | Small-cell lung cancer | II | 84 | NCT03371979 | Active, not recruiting |
131I-TLX-101 | LAT1 | Glioblastoma multiforme | II | 44 | NCT03849105 | Recruiting |
Rifampicin | FAS | Advanced solid tumors | I | 36 | NCT03077607 | Completed, has results |
TVB-2640 | Advanced breast cancer | II | 80 | NCT03179904 | Recruiting | |
IM156 | AMPK | Advanced solid tumor | I | 36 | NCT03272256 | Recruiting |
Telaglenastat | Glutaminase | Solid tumors | II | 85 | NCT03965845 | Recruiting |
CB-1158 | Arginase | Advanced solid tumors | II | 5 | NCT03361228 | Completed |
Niche inhibitors | ||||||
Plerixafor (Mozobil) | CXCR4 | Advanced pancreatic, ovarian, and colorectal cancers | I | 26 | NCT02179970 | Completed |
BL-8040 | Metastatic pancreatic adenocarcinoma | II | 23 | NCT02907099 | Active, not recruiting | |
BKT140 | Multiple myeloma | II | 16 | NCT01010880 | Completed | |
BMS-936564 | Relapsed/refractory multiple myeloma | I | 46 | NCT01359657 | Completed | |
BMS-936564 | Acute myelogenous leukemia | I | 98 | NCT01120457 | Completed | |
LY2510924 | Solid tumor | I | 9 | NCT02737072 | Terminated, has results | |
MSX-122 | Refractory metastatic or locally advanced solid tumors | I | 27 | NCT00591682 | Suspended | |
USL311 | Advanced solid tumors and relapsed/recurrent Glioblastoma multiforme | II | 120 | NCT02765165 | Recruiting | |
AMD3100 | Acute myeloid leukemia | II | 52 | NCT00512252 | Completed, has results | |
Reparixin | CXCR1/2 | Breast cancer | II | 20 | NCT01861054 | Terminated |
Defactinib (VS-6063) | FAK | Non-small-cell lung cancer | II | 55 | NCT01951690 | Completed |